Search

everythinglearnresearchcommunity

for

Search:↓

Nonclassic congenital adrenal hyperplasia is a genetic disorder causing hormone imbalances, affecting fertility and requiring personalized treatment.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

Small changes in hormones can significantly impact health, showing the importance of sensitive testing for chemicals that disrupt hormones.

Finasteride and minoxidil are effective FDA-approved treatments for androgenetic alopecia.

Certain genetic variations are linked to increased androgen levels in PCOS, but more research is needed to understand these connections fully.

Women with excessive male-pattern hair growth should get a full hormone check-up to find and treat any underlying issues, considering both medical and emotional aspects.

With careful management, people with congenital adrenal hyperplasia can have successful pregnancies and become parents.

Finasteride doesn't affect bone density in male rats.

Antiandrogens are effective for conditions like prostate cancer and skin issues, but more research is needed to confirm their benefits and minimize side effects.

Testosterone therapy seems safe and effective for transgender men with proper care, but more long-term research is needed.

Women with PCOS have higher levels of AMH in their blood and follicles, and this can help predict their risk of overreaction to fertility treatments.

Women with PCOS who had antiandrogenic treatment before pregnancy had fewer complications than those without treatment.

The research found that MRI and certain hormone levels can help tell apart ovarian tumors from hyperthecosis in postmenopausal women, but tissue analysis is still needed for a definite diagnosis.

Daughters of women with PCOS generally experience normal puberty but may have more body hair and different body fat distribution.

The document concludes that using LC-MS/MS for measuring androgens is more accurate than older methods, but it needs careful validation and standardized references to be most effective.

PCOS is a complex disorder managed by treating symptoms and requires a team of specialists.

Stump-tailed macaque best for researching hair loss causes and treatments.

Finasteride significantly reduces hair growth in women with idiopathic hirsutism.

Insulin resistance is linked to high male hormone levels in women, often seen in those with PCOS.

PCOS may start before birth, involves metabolic issues, and can be treated with drugs like metformin and lifestyle changes.

Using computers to analyze drugs can find new uses for them, but actual experiments are needed to confirm these uses.

Hormonal therapy is a treatment option for acne, the only medical treatment for hirsutism, and the most promising for androgenetic alopecia.

Researchers found an RNA transcript that might help control a growth factor linked to tumor development.

New male hormonal contraceptives show promise but need more research on long-term effects and funding for larger trials.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

Many treatments for hair loss lack proper testing and FDA approval, so their effectiveness is uncertain.

Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.

High-intensity interval training improves certain hormone levels and lipid profiles in women with PCOS.

The conclusion suggests that PCOS may persist due to genetic traits that, while harmful for female fertility, could have provided survival and reproductive benefits to males.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.